Nicotinic Agonist Effects on BMI and Neuronal Response
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 65 |
| Updated: | 1/31/2019 |
| Start Date: | November 2015 |
| End Date: | June 2020 |
| Contact: | Kristina T Legget, Ph.D. |
| Email: | kristina.legget@ucdenver.edu |
| Phone: | 303-724-5809 |
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
Obesity is a serious and growing health problem in the United States. Obesity is associated
with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased
quality of life and increased mortality. Given the health and quality-of-life effects of
obesity, developing effective treatments clearly is an important goal.
This study plans to learn more about the effects of an investigational new drug (DMXB-A
(3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has
similar effects to nicotine. Since nicotine has been found to affect appetite, the
investigators are interested in studying effects of the study drug, which has some
similarities to nicotine, on how your brain responds to such things as pictures of food. The
study drug has not been approved by the Food and Drug Administration (FDA), and is considered
experimental.
with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased
quality of life and increased mortality. Given the health and quality-of-life effects of
obesity, developing effective treatments clearly is an important goal.
This study plans to learn more about the effects of an investigational new drug (DMXB-A
(3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has
similar effects to nicotine. Since nicotine has been found to affect appetite, the
investigators are interested in studying effects of the study drug, which has some
similarities to nicotine, on how your brain responds to such things as pictures of food. The
study drug has not been approved by the Food and Drug Administration (FDA), and is considered
experimental.
Inclusion Criteria:
- Overweight/obese (BMI > 27)
- Between 21-65 years old
Exclusion Criteria:
- Known cardiovascular disease (e.g., coronary artery disease, uncontrolled hypertension
- Women capable of conception (must be post-menopausal, surgically sterilized, or have
adhered to an anti-contraception birth control regimen for at least 1 year)
- Nicotine use
- Significant endocrine/metabolic disease
- Kidney disease
- Neurological illness
- Liver disease
- Medication use affecting appetite and/or metabolism
- MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)
We found this trial at
1
site
Click here to add this to my saved trials
